

## Prioritising patient safety and public health across Europe post- Brexit

The UK leaving the EU will have significant implications for patients and the public. It is essential that patients' interests are put first in Brexit negotiations. Our organisations are working together to ensure that decision-makers are clear on what steps are needed to ensure patients are put first.



*\*FEAM has endorsed this statement on behalf of its Academies in the European Union*

## Prioritising patient safety and public health across Europe post-Brexit

As a decision-maker, we ask you to focus on achieving the following objectives in negotiations, to ensure the best deal is struck for patients and public across Europe.

<p><b>1. To ensure that EU27 and UK patients continue having access to life-saving drugs and medical technologies*, and early access to new health technologies post-Brexit, we urge you to achieve:</b></p> <ul style="list-style-type: none"><li>• Close cooperation and mutual recognition between the EU and the UK on the regulation of medicines and medical technologies.</li><li>• Full alignment of the UK to the EU regulatory framework for medicines and medical technologies.</li><li>• Seamless trade between the EU and UK to avoid disruptions in the manufacturing and supply of medicines and medical technologies.</li><li>• The highest standards of patient safety through the UK's continued participation in EU systems, such as data sharing networks, pharmacovigilance and the clinical trials portal, Eudamed (the EU database for medical devices and <i>in vitro</i> medical devices) and all related databases post-Brexit.</li></ul>
<p><b>2. To ensure the EU remains a world class hub for research and collaboration post-Brexit, we collectively urge you to seek:</b></p> <ul style="list-style-type: none"><li>• A common framework for collaboration in research and information-sharing between the EU27 and the United Kingdom to ensure that post-Brexit EU27 and UK patients, the public, researchers and organisations can take part in pan-European research and innovation networks and clinical trials.</li></ul>
<p><b>3. To ensure that EU27 and UK patients continue to receive the best possible care, wherever they need it, we call on you to achieve:</b></p> <ul style="list-style-type: none"><li>• Continued reciprocal healthcare arrangements for both those who have crossed the border before Brexit day and for post-Brexit flows.</li><li>• EU citizens travelling to the UK and vice versa continue to benefit from the EHIC for urgent and emergency care.</li></ul>
<p><b>4. To ensure that public health for all EU and UK citizens is maintained post-Brexit we collectively call on you to secure:</b></p> <ul style="list-style-type: none"><li>• Strong coordination between the EU and UK to deal with pandemics, as well as other health threats.</li><li>• Highest possible level of coordination between the EU and UK on health promotion and disease prevention programmes.</li></ul>
<p><b>5. To ensure that EU27 and UK health professionals continue to benefit from mutually beneficial training and education opportunities, automatic recognition of their qualifications, and can continue to provide healthcare services to EU27 and UK patients, we call on you to achieve:</b></p> <ul style="list-style-type: none"><li>• In the EU27 and the UK, continued recognition of professional qualifications of general practice nurses, medical doctors, dentists, pharmacists and midwives trained in the EU27 and the UK before Brexit day and for post-Brexit;</li><li>• That EU27 and UK competent authorities continue to use the alert mechanism through the Internal Market Information System to alert each other of health professionals who are prohibited or restricted to practice.</li></ul>

\*medical devices and in vitro diagnostic medical devices